×
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
NASDAQ:FMTX

Forma Therapeutics Stock Forecast, Price & News

$7.03
-0.21 (-2.90%)
(As of 06/24/2022 04:00 PM ET)
Add
Compare
Today's Range
$6.72
$7.45
50-Day Range
$5.10
$8.38
52-Week Range
$4.95
$26.61
Volume
1.29 million shs
Average Volume
593,244 shs
Market Capitalization
$336.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$45.20
30 days | 90 days | 365 days | Advanced Chart

Receive FMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Forma Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FMTX Stock Forecast (MarketRank)

Overall MarketRank

1.93 out of 5 stars

Medical Sector

663rd out of 1,418 stocks

Biological Products, Except Diagnostic Industry

105th out of 216 stocks

Analyst Opinion: 3.5Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
Forma Therapeutics logo

About Forma Therapeutics (NASDAQ:FMTX)

Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts.

FMTX Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FMTX
Fax
N/A
Employees
166
Year Founded
N/A

Company Calendar

Last Earnings
5/06/2022
Today
6/24/2022
Next Earnings (Estimated)
8/12/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$45.20
High Stock Price Forecast
$58.00
Low Stock Price Forecast
$23.00
Forecasted Upside/Downside
+543.0%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
4 Analysts

Profitability

Net Income
$-172.96 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$100.56 million
Book Value
$10.51 per share

Miscellaneous

Free Float
45,037,000
Market Cap
$336.07 million
Optionable
Not Optionable
Beta
0.44














Forma Therapeutics Frequently Asked Questions

Should I buy or sell Forma Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Forma Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Forma Therapeutics stock.
View analyst ratings for Forma Therapeutics
or view top-rated stocks.

What is Forma Therapeutics' stock price forecast for 2022?

4 analysts have issued 12-month price targets for Forma Therapeutics' shares. Their FMTX stock forecasts range from $23.00 to $58.00. On average, they expect Forma Therapeutics' share price to reach $45.20 in the next year. This suggests a possible upside of 543.0% from the stock's current price.
View analysts' price targets for Forma Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Forma Therapeutics' stock performed in 2022?

Forma Therapeutics' stock was trading at $14.22 on January 1st, 2022. Since then, FMTX shares have decreased by 50.6% and is now trading at $7.03.
View the best growth stocks for 2022 here
.

When is Forma Therapeutics' next earnings date?

Forma Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our earnings forecast for Forma Therapeutics
.

How were Forma Therapeutics' earnings last quarter?

Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) posted its quarterly earnings data on Friday, May, 6th. The company reported ($0.93) earnings per share for the quarter, beating the consensus estimate of ($1.04) by $0.11. During the same period in the previous year, the company earned ($0.76) EPS.
View Forma Therapeutics' earnings history
.

Who are Forma Therapeutics' key executives?

Forma Therapeutics' management team includes the following people:
  • Mr. Frank D. Lee, Pres, CEO & Director (Age 54, Pay $963.2k) (LinkedIn Profile)
  • Mr. Todd E. Shegog, Sr. VP & CFO (Age 56, Pay $620.25k)
  • Dr. Patrick F. Kelly M.D., Sr. VP & Chief Medical Officer (Age 57, Pay $636.58k) (LinkedIn Profile)
  • Dr. John E. Bishop Ph.D., Sr. VP & Chief Technology Officer (Age 60)
  • Dr. David N. Cook Ph.D., Sr. VP & Chief Scientific Officer (Age 64)
  • Mr. Mario Vincent Corso C.F.A., Head of Investor Relations
  • Dr. Jeannette Potts J.D., Ph.D., Sr. VP, Gen. Counsel & Corp. Sec. (Age 60) (LinkedIn Profile)
  • Ms. Mary E. Wadlinger, Sr. VP of Corp. Affairs & Chief HR Officer (Age 62)
  • Mr. Brian Lesser, Sr. VP of Commercial (Age 47)
  • Dr. Ifeyinwa Osunkwo M.D., M.P.H., Sr. VP & Chief Patient Officer

What other stocks do shareholders of Forma Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Forma Therapeutics investors own include Boeing (BA), Marvell Technology (MRVL), Trade Desk (TTD), Abbott Laboratories (ABT), CVS Health (CVS), Walt Disney (DIS), DocuSign (DOCU), Gilead Sciences (GILD), Intuit (INTU) and Neurocrine Biosciences (NBIX).

When did Forma Therapeutics IPO?

(FMTX) raised $201 million in an initial public offering on Friday, June 19th 2020. The company issued 11,800,000 shares at a price of $16.00-$18.00 per share. Jefferies' SVB Leerink and Credit Suisse acted as the underwriters for the IPO.

What is Forma Therapeutics' stock symbol?

Forma Therapeutics trades on the NASDAQ under the ticker symbol "FMTX."

Who are Forma Therapeutics' major shareholders?

Forma Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.37%), State Street Corp (5.91%), Vanguard Group Inc. (4.77%), Deep Track Capital LP (3.50%), Renaissance Technologies LLC (1.35%) and Northern Trust Corp (0.66%). Company insiders that own Forma Therapeutics stock include Frank D Lee, Jeannette Potts, Patrick F Kelly and Todd Shegog.
View institutional ownership trends for Forma Therapeutics
.

Which major investors are selling Forma Therapeutics stock?

FMTX stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Citigroup Inc., Goldman Sachs Group Inc., Charles Schwab Investment Management Inc., BlackRock Inc., California State Teachers Retirement System, ProShare Advisors LLC, and Bank of America Corp DE. Company insiders that have sold Forma Therapeutics company stock in the last two years include Frank D Lee, Jeannette Potts, Patrick F Kelly, and Todd Shegog.
View insider buying and selling activity for Forma Therapeutics
or view top insider-selling stocks.

Which major investors are buying Forma Therapeutics stock?

FMTX stock was bought by a variety of institutional investors in the last quarter, including Deep Track Capital LP, State Street Corp, Renaissance Technologies LLC, Silverarc Capital Management LLC, Bollard Group LLC, PDT Partners LLC, Qube Research & Technologies Ltd, and Invesco Ltd..
View insider buying and selling activity for Forma Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Forma Therapeutics?

Shares of FMTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Forma Therapeutics' stock price today?

One share of FMTX stock can currently be purchased for approximately $7.03.

How much money does Forma Therapeutics make?

Forma Therapeutics (NASDAQ:FMTX) has a market capitalization of $336.07 million and generates $100.56 million in revenue each year. The company earns $-172.96 million in net income (profit) each year or ($3.820010) on an earnings per share basis.

How many employees does Forma Therapeutics have?

Forma Therapeutics employs 166 workers across the globe.

How can I contact Forma Therapeutics?

Forma Therapeutics' mailing address is 500 ARSENAL STREET SUITE 100, WATERTOWN MA, 02472. The official website for Forma Therapeutics is www.formatherapeutics.com. The company can be reached via phone at 617-679-1970 or via email at [email protected].

This page (NASDAQ:FMTX) was last updated on 6/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.